Copy
Problems viewing this newsletter? View it in your browser >



July 14, 2010

Dear Advocate,

Today, we are delighted to release AVAC Report 2010: Turning the Page. Our 13th annual report, Turning the Page surveys, critiques and proposes recommendations for the field of biomedical prevention research: AIDS vaccines, microbicides and ARV-based prevention strategies such as PrEP and treatment as prevention. 

Click here to download the complete Report or specific sections, figures or boxes of interest. 

Click here for our press release. 

As the global AIDS community prepares for next week's International AIDS Conference in Vienna, AVAC Report 2010 provides context and a unique perspective on some of the key themes expected to emerge at the meeting. 

We've called the Report "Turning the Page" because the biomedical prevention field has entered the next chapter of its development. The past year brought the first evidence, from the Thai Prime-Boost trial, that an AIDS vaccine could prevent HIV in humans, as well as significant preclinical findings around potent, HIV-specific neutralizing antibodies. At the same time, two microbicide trials testing the candidate PRO 2000 yielded seemingly different, but ultimately disappointing results, and the field now prepares for the release--in Vienna--of results from CAPRISA 004, the first ARV-based microbicide effectiveness trial. 

What needs to happen next to ensure that the vaccine field capitalizes on the momentum from the Thai Prime-Boost trial? 

See our first chapter, Proof of Concept and its Consequences: Making sense of the post-RV144 world, which evaluates the paths the vaccine field could take forward following this historic trial. 

How successful was community engagement in the largest AIDS vaccine trial in history?

Read our second chapter, The Thai Way Forward: What comes after the largest AIDS vaccine trial in the world?, for on-the-ground reports on some of the difficult situations and hard-won solutions that emerged over the course of the Thai Prime-Boost study.

Is the AIDS vaccine field doing all that it can with the data and materials it has amassed or aims to collect? 

Chapter Three of the Report, Data and Materials: A "to-do" list for the future, looks at strengths and weaknesses in the field's approach to data and materials, the "bricks and mortar" of research. 

What kinds of trials will provide answers to the complex questions emerging in the microbicide, PrEP and vaccine fields? 

The Report's fourth chapter, Trials and Trial Design: Where does prevention research go from here?, probes some of the proposals currently in the works for future studies.

Is the world ready for the promise and pitfalls of ARV-based prevention strategies for HIV-positive and HIV-negative people? 

Speak with One Voice, Work Towards One Goal, the Report's conclusion, lays out the need--now more than ever--to bring the prevention and treatment threads into a single conversation and agenda for action.

AVAC Report 2010 is just one of the publications we will be releasing around the Vienna AIDS conference. You can follow the news from Vienna on our dedicated webpage, avac.org/AIDS2010, and if you're in Vienna, pick up a copy of Turning the Page at the AVAC booth (E-409) in the exhibition hall. You can also order printed copies at avac.org/avac-publications

As always, questions and comments are welcome--please email us!

Best,

AVAC


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: avac@avac.org

W: www.avac.org